Keywords
How to Cite
Abstract
The bleeding disorder in patients with factor XI deficiency has presented practical and conceptual challenges for clinicians and basic scientists.
In FXI deficient patients, the most frequent symptoms are menorrhagia and epistaxis, while severe
spontaneous hemorrhage is rare. However, current diagnostic tests can not accurately predict bleeding trends in patients with FXI deficiency, since the symptoms are highly variable among patients and are poorly correlated with plasma FXI levels.
The objective of this study was to perform a retrospective study of 14 patients with FXI deficiency
who attended the Hematology Service of the British Hospital of Buenos Aires between 2007 and 2019.
Fourteen patients who attended the Hematology Service with prolonged APTT or bleeding were studied
The mean age was 52 years. The average of FXI levels in the patients was 31%. Five patients were studied for their personal bleeding history (FXI level between 0.1% and 48%) and nine patients were diagnosed during the pre-surgical examination. The main reason for medical consultation was for scheduled surgery.
The mean of the APTT was 54 seconds (range: 40-90). All presented correction with normal pool. Five patients with severe FXI deficiency (<15%) showed an APTT between 54 and 90 seconds (mean 70.8).
In this group of patients, we found patients with severe FXI deficiency who did not bled (FXI level <15%) and patients with mild deficiencies who bled. This discrepancy observed between the level of FXI and the clinical manifestations agrees with that reported in the literature.
Due to the lack of an easily accessible test, which discriminates against patients at risk of bleeding from those who do not, all patients with FXI levels of less than 40% received treatment before any surgical procedure.
References
2. Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016 Jul; 9 (7): 629-37.
3. Preis M, Hirsch J, Kotler A. Factor XI deficiency is associated with lower risk for cardiovascular and
venous thromboembolism events. Blood. 2017 Mar 2;129(9):1210.
4. Puy C, Rigg RA, McCarty OJ. The hemostatic role of factor XI. Thromb Res. 2016 May;141 Suppl 2:S8-S11.
5. Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets of antithrombotic therapy. J Thromb Haemost. 2015;13:1383-95.
6. Matafonov A, Sarilla S, Sun MF. Activation of factor XI by products of prothrombin activation. Blood. 2011;118:437-45.
7. Morrissey JH, Smith SA. Polyphophate as a modulator of hemostasis, thrombosis and inflammation. J Thromb Haemost. 2015;13(Suppl 1):S92-97.
8. Vincent LM, Tran S, Livaja R. Coagulation factor V(A2440G) causes east Texas bleeding disorder via
TFPIα. J Clin Invest. 2013;123:3777-87.
9. Zucker M, Seligsohn U, Salomon O, Wolberg AS. Abnormal plasma clot structure and stability distinguish
bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost. 2014;12:1121-30.
10. Colucci F, Incampo A, Cannav O. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathwayM. J Thromb Haemost. 2016 Aug;14(8):1603-14.
11. Dai L, Mitchell M, Savidge G. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis. J Thromb Haemost. 2004;2: 2200.
12. Duboscq C. El Sistema plasminógeno plasmina. Fisiología de la Hemostasia Normal. Hematología. 2017;21:56-68.
13. Livnat T, Shenkman B, Martinowitz U et al. The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thromb Res. 2015;136:465-73.
14. Pike GN, Cumming AM, Hay CR. Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency. Blood. 2015; 12:397-405.
15. Matafonov A, Sarilla S, Sun MF. Activation of factor XI by products of prothrombin activation. Blood. 2011; 118:437-45.
16. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood. 2011;118:6963-6970.
17. Pike GN, Cumming AM, Thachil J. Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency. Haemophilia. 2017;23:449-457.
18. James P, Salomon O, Mikovic D, Peyvandi F. Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia. 2014; 20(Suppl 4):71-5.
19. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7(Suppl 1):84-7.
20. Salomon O, Zivelin A, Livnat T et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003; 101:4783-4788.
21. Bowman M, Mundell G, Grabell J. Generation and validation of the Condensed MCMDM-1VWD Bleeding
Questionnaire for von Willebrand disease. J Thromb Haemost. 2008; 6:2062-6.
22. Mumford AD, Ackroyd S, Alikhan R et al. Guideline for the diagnosis and management of the rare coagulation. Br J Haematol. 2014;167:304-26.
23. Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood. 2015 Jul 16; 126(3):397-405.
24. Davies J, Kadir R. The Management of Factor XI Deficiency in Pregnancy. Semin Thromb Hemost. 2016 Oct; 42(7):732-740.
25. Santoro C, Di Mauro R, Baldacci E et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015;21:496-501.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar